Dexamethasone Therapy Interferes with the Development of the Neutrophil Oxidative Burst In Vitro in Very Low Birthweight Infants

ABSTRACT

Dexamethasone therapy is used in the treatment of chronic lung disease in very low birthweight (VLBW) neonates. However, several significant side effects have been observed in these patients, including an increased incidence of infection. We initiated a pilot study to examine the in vitro function of neutrophils from dexamethasone-treated VLBW infants. Following a 1-week course of dexamethasone, VLBW infants failed to demonstrate the increased oxidative burst that was observed in the age- and weight-matched untreated infants. These observations support recent evidence raising concern about effects on other organs when using dexamethasone in mechanically ventilated infants. In this example, impaired oxidative burst may be among the cellular factors contributing to the increased risk of infection during corticosteroid use in VLBW neonates in the neonatal intensive care setting.

KEYWORDS

Corticosteroids - oxidative burst - VLBW neonates - neutrophils

REFERENCES

• 1 Yeh T F, Lin Y J, Hsieh W S et al.. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial.  Pediatrics. 1997;  100 e3
• 2 Stoll B J, Temprosa M, Tyson J E et al.. Dexamethasone therapy increases infection in very low birth weight infants.  Pediatrics. 1999;  104 e63
• 3 American Academy of Pediatrics and Canadian Paediatric Society . Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.  Pediatrics. 2002;  109 330-338
• 4 Halliday H L. Postnatal steroids and chronic lung disease in the newborn.  Paediatr Respir Rev. 2004;  5(suppl A) S245-S248
• 5 Perticarari S, Presani G, Mangiarotti M A, Banfi E. Simultaneous flow cytometric method to measure phagocytosis and oxidative burst products by neutrophils.  Cytometry. 1991;  12 687-693
• 6 Ahmad M, Fleit H B, Golightly M G, La Gamma E F. In vivo effect of recombinant human granulocyte colony-stimulating factor on phagocytic function and oxidative burst activity in septic neutropenic neonates.  Biol Neonate. 2004;  86 48-54
• 7 Goulding N J, Euzger H S, Butt S K, Perretti M. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation.  Inflamm Res. 1998;  47(suppl 3) S158-S165
• 8 Rocksen D, Lilliehook B, Larsson R, Johansson T, Bucht A. Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation.  Clin Exp Immunol. 2000;  122 249-256
• 9 O'Leary E C, Evans G F, Zuckerman S H. In vivo dexamethasone effects on neutrophil effector functions in a rat model of acute lung injury.  Inflammation. 1997;  21 597-608
• 10 Ballabh P, Simm M, Kumari J et al.. Respiratory burst activity in bronchopulmonary dysplasia and changes with dexamethasone.  Pediatr Pulmonol. 2003;  35 392-399
• 11 Habermehl P, Hauer T, Mannhardt W, Knuf M, Zepp F, Schofer O. Granulocyte function in premature infants before the 34th week of pregnancy and in mature newborn infants.  Klin Padiatr. 1999;  211 149-153
• 12 La Gamma E F, De Castro M H. What is the rationale for the use of granulocyte and granulocyte-macrophage colony stimulating factors in the neonatal intensive care unit?.  Acta Paediatr Suppl. 2002;  91 109-116
• 13 Roilides E, Uhlig K, Venzon D, Pizzo P A, Walsh T J. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon.  Infect Immun. 1993;  61 4870-4877